Blood Sugar, Inflammation, and Antimicrobial Properties

How Laurus nobilis — the common culinary bay leaf — supports blood glucose control, reduces inflammation, and fights harmful microbes.

Bay leaf (Laurus nobilis) is one of the most familiar herbs in the kitchen, but it does considerably more than flavor soups and stews. Research shows that the same dried leaf can meaningfully lower blood glucose and cholesterol in people with type 2 diabetes [1], suppress a key driver of chronic inflammation [2], and protect cells from the metabolic stress that leads to insulin resistance [3]. Its essential oil is dense with bioactive compounds — 1,8-cineole, linalool, and eugenol — that give it broad antimicrobial activity as well [4].

How Bay Leaf Works in the Body

Bay leaf's health effects come from a cluster of bioactive compounds, most concentrated in the essential oil and polar extracts of the dried leaf.

1,8-Cineole (eucalyptol) makes up roughly a third of the essential oil [4]. It is the compound most directly linked to bay leaf's anti-inflammatory action: laboratory research shows it suppresses the NLRP3 inflammasome, a protein complex that, when over-activated, drives interleukin-1β release and the low-grade chronic inflammation associated with metabolic disease, arthritis, and cardiovascular conditions [2].

Eugenol (6–12% of the essential oil) inhibits prostaglandin synthesis through a mechanism similar to non-steroidal anti-inflammatory drugs, adding an analgesic and anti-inflammatory layer distinct from the cineole pathway [4].

Polyphenols and tannins in the leaf — including flavonoids and catechins — appear to improve insulin signalling. In cell-line research using human liver cells exposed to both high glucose and high insulin, bay leaf extract significantly reduced reactive oxygen species, restored mitochondrial function, and reversed markers of insulin resistance. The researchers identified improved mitochondrial biogenesis as a likely mechanism [3].

Blood glucose and lipid effects in humans: a randomised controlled trial assigned 40 people with type 2 diabetes to take capsules of ground bay leaf (1 g, 2 g, or 3 g daily) or placebo for 30 days. All three doses produced significant reductions in fasting blood glucose (21–26%), total cholesterol (20–24%), LDL cholesterol (26–34%), and triglycerides (34–40%), while HDL cholesterol rose. The placebo group showed no change [1].

Practical use

The easiest way to incorporate bay leaf is the way it has always been used — simmering several dried leaves in soups, broths, bean dishes, and grains. The clinical trial used ground leaf in capsule form, so cooking with whole leaves over long periods almost certainly delivers less total extract than a concentrated dose. That said, even culinary quantities provide meaningful amounts of cineole and polyphenols, particularly in long-simmered dishes.

For those looking at therapeutic use, the study doses were 1–3 g of ground dried leaf per day — roughly one to three medium bay leaves finely ground. Some practitioners add ground bay leaf to smoothies, teas, or rice dishes. Avoid swallowing whole or large pieces of dried leaf, which are sharp.

Bay leaf pairs well with other blood-sugar-supportive cooking habits. See our cinnamon page and berberine page for complementary approaches.

Evidence Review

Human clinical trial: blood glucose and lipid effects

Khan et al. (2009) conducted the only published randomised controlled trial examining bay leaf in humans with metabolic disease [1]. Forty adults with type 2 diabetes were randomised to 1 g, 2 g, or 3 g of ground bay leaf daily in capsule form versus placebo for 30 days. All participants were on existing diabetes management.

Outcomes at 30 days:

Fasting serum glucose: reduced 21% (1 g), 23% (2 g), and 26% (3 g) versus baseline; placebo unchanged
Total cholesterol: reduced 20% (1 g), 24% (2 g), and 24% (3 g)
LDL: reduced 26%, 29%, and 34% across doses
Triglycerides: reduced 34%, 25%, and 40% across doses
HDL: increased 20%, 29%, and 20% across doses

All changes were statistically significant. The trial was conducted at Bacha Khan Medical College, Pakistan, and funded independently of industry. Limitations include the short duration (30 days), relatively small sample size (n = 40), and a single-site design. The mechanism was not investigated at the cellular level, but the authors suggested bay leaf's polyphenols enhance insulin receptor sensitivity.

This result is biologically plausible given subsequent mechanistic research (see below) and the known activity of polyphenols on GLUT4 translocation and pancreatic beta-cell function.

Anti-inflammatory mechanism: NLRP3 inflammasome suppression

Lee et al. (2019) investigated bay leaf's anti-inflammatory mechanism in macrophage and dendritic cell models [2]. The NLRP3 inflammasome is a multiprotein complex that senses cellular stress signals and triggers IL-1β secretion — a potent pro-inflammatory cytokine implicated in gout, type 2 diabetes, atherosclerosis, and metabolic syndrome.

Bay leaf extract inhibited:

Caspase-1 activation (the enzyme that cleaves pro-IL-1β into its active form)
IL-1β secretion
Formation of ASC pyroptosome complexes (the structural core of the NLRP3 inflammasome)

The active compound responsible was 1,8-cineole. Fractionation experiments confirmed that cineole alone, at concentrations found in leaf extracts, reproduced the full inflammasome-suppressing effect. This positions bay leaf as one of several food-derived compounds (alongside quercetin and sulforaphane) that target NLRP3 specifically, rather than just broadly suppressing immune activity.

The study was in vitro (cell culture), which limits direct translation to human tissue. However, 1,8-cineole is well-absorbed orally and reaches physiologically relevant concentrations in plasma, supporting its relevance as a therapeutic agent.

Insulin resistance and mitochondrial protection

Bourebaba et al. (2021) used HepG2 human liver carcinoma cells as a model of hyperglycaemia and hyperinsulinaemia-induced insulin resistance [3]. This cell line is widely used to study hepatic glucose metabolism because it retains key insulin signalling pathways.

Bay leaf ethanolic extract treatment:

Significantly reduced total intracellular reactive oxygen species (ROS)
Restored mitochondrial membrane potential, which is disrupted under high glucose/insulin conditions
Improved markers of mitochondrial biogenesis (PGC-1α, TFAM expression)
Reduced apoptotic cell death
Improved insulin receptor substrate (IRS-1) phosphorylation, a key early step in insulin signalling

The authors proposed that bay leaf's polyphenols act primarily through the oxidative stress pathway: high glucose and insulin produce ROS, which damage mitochondria and impair the insulin signalling cascade. Bay leaf extract interrupts this cycle by scavenging ROS and supporting mitochondrial repair. This mechanism is consistent with findings from other plant polyphenols such as resveratrol and curcumin.

Limitations: this is a cell-culture study and the concentrations used may exceed what is achievable through dietary intake alone. Clinical translation requires human trials with hepatic outcome measures.

Essential oil composition and antimicrobial activity

Caputo et al. (2017) analysed the essential oil of bay leaf harvested in southern Italy and identified 55 compounds [4]. The major constituents were:

1,8-Cineole: 31.9%
Sabinene: 12.2%
Linalool: 10.2%
α-Terpinyl acetate: 9.4%

The oil showed broad-spectrum antimicrobial activity against food-borne and opportunistic pathogens including Staphylococcus aureus, Bacillus cereus, Escherichia coli, and Candida albicans, using standard minimum inhibitory concentration assays. 1,8-Cineole was the primary active agent against most organisms tested.

The researchers also found that the essential oil affected the expression of adenylate cyclase 1 (ADCY1) in SH-SY5Y neuroblastoma cells, raising the possibility of effects on cAMP signalling in the central nervous system — an area that warrants further research but remains preliminary.

Strength of evidence

The blood glucose finding from Khan et al. is supported by a genuine randomised controlled trial in humans with metabolic disease, which is unusual for a culinary herb. The effect sizes (21–26% glucose reduction over 30 days) are clinically meaningful and comparable to some pharmaceutical interventions. However, replication in larger, multi-site trials has not been published, which is a significant gap. Mechanistic support from the NLRP3 and mitochondrial studies reinforces biological plausibility.

The anti-inflammatory and antioxidant findings are robust at the laboratory level but lack human trial confirmation. Bay leaf is safe as a food ingredient at culinary amounts, and at therapeutic doses (1–3 g/day of ground leaf) no adverse effects were reported in the published trial. Persons on blood glucose-lowering medication should monitor levels if adding therapeutic doses, given the potential additive effect on glucose.

References

Bay leaves improve glucose and lipid profile of people with type 2 diabetesKhan A, Zaman G, Anderson RA. Journal of Clinical Biochemistry and Nutrition, 2009. PubMed 19177188 →
Laurus nobilis leaf extract controls inflammation by suppressing NLRP3 inflammasome activationLee EH, Shin JH, Kim SS, Lee H, Yang SR, Seo SR. Journal of Cellular Physiology, 2019. PubMed 30387132 →
Laurus nobilis ethanolic extract attenuates hyperglycemia and hyperinsulinemia-induced insulin resistance in HepG2 cell line through the reduction of oxidative stress and improvement of mitochondrial biogenesisBourebaba N, Kornicka-Garbowska K, Marycz K, Bourebaba L, Kowalczuk A. Mitochondrion, 2021. PubMed 34091077 →
Laurus nobilis: Composition of Essential Oil and Its Biological ActivitiesCaputo L, Nazzaro F, Souza LF, Aliberti L, De Martino L, Fratianni F, Coppola R, De Feo V. Molecules, 2017. PubMed 28587201 →